common.study.topics.clinical

Systemic Lupus Erythematosus Trial

common.study.values.description

A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The main objective of this study is to evaluate the safety and efficacy of ABBV-105, upadacitinib, and ABBV-599 vs placebo for the treatment of signs and symptoms of SLE in participants with moderately to severely active SLE and to define doses for further development.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - ABBV-105

ABBV-105 is administered orally as capsule

Drug - Placebo for ABBV-105

Placebo for ABBV-105 is administered orally as capsule

Drug - Upadacitinib

Upadacitinib is administered orally as a tablet

Drug - Placebo for upadacitinib

Placebo for upadacitinib is administered orally as a tablet

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

common.study.values.clinical-trial-id

NCT03978520

participant.views.study.view.id

av2p5a